Mycotoxin Specific Neutra™ Antibody Products

Are you challenged by inefficient mycotoxin detection, limited specificity in neutralization, or delays in therapeutic validation? Creative Biolabs' mycotoxin specific Neutra™ antibody products leverage high-affinity hybridoma technology and epitope-directed engineering to deliver rigorously validated antibodies, enabling rapid toxin quantification, reliable research outcomes, and streamlined therapeutic development.

Introduction to Mycotoxin

Mycotoxins are toxic secondary metabolites produced by fungi, primarily Aspergillus, Fusarium, and Penicillium species, contaminating food crops and livestock feed. These small-molecule toxins are chemically stable, heat-resistant, and biologically persistent, posing global threats to food safety, animal health, and human populations. Exposure occurs via ingestion, inhalation, or dermal contact, with severe outcomes in acute and chronic toxicity.

• Structural Diversity

Mycotoxins exhibit varied chemical frameworks: aflatoxins feature a difuranocoumarin backbone, ochratoxins contain a dihydroisocoumarin moiety linked to phenylalanine, and zearalenone mimics estrogen with a resorcylic acid lactone structure. These structural motifs determine their mechanisms of toxicity, such as DNA adduct formation (aflatoxin B1) or hormonal disruption (zearalenone).

• Pathogenic Signaling Pathways

Mycotoxins disrupt cellular homeostasis by targeting critical pathways:

- Oxidative Stress: Deoxynivalenol (DON) activates MAPK and NF-κB pathways, triggering pro-inflammatory cytokine release.

- Apoptosis: Fumonisins inhibit ceramide synthase, disrupting sphingolipid metabolism and promoting hepatocyte death.

- Carcinogenesis: Aflatoxin B1 metabolites form DNA adducts, inducing p53 mutations and hepatocellular carcinoma.

Fig.1 Molecular mechanism of mycotoxin exposure-induced cell apoptosis and oxidative stress.¹

• Associated Diseases

Chronic exposure leads to immunosuppression, organ damage (liver, kidney), and cancer. Aflatoxins are classified as Group 1 carcinogens, responsible for 30% of global hepatocellular carcinoma cases. Ochratoxin A accumulates in renal tubules, causing nephropathy and Balkan endemic nephropathy. Zearalenone contributes to reproductive disorders in livestock and endocrine disruption in humans.

Applications of Mycotoxin Neutralizing Antibodies

• Rapid Diagnostic Assays for Food Safety

Antibodies are integrated into lateral flow devices and ELISA kits for on-site detection of mycotoxin contamination in crops, dairy, and processed foods. These tools enable compliance with regulatory thresholds (e.g., EU limits for aflatoxin B1 at 2 ppb) and prevent toxin entry into supply chains.

• Therapeutic Intervention in Mycotoxicosis

Neutralizing antibodies administered intravenously bind circulating mycotoxins in acute poisoning cases, reducing bioavailability and organ damage. Preclinical studies demonstrate efficacy in lowering aflatoxin-induced hepatic necrosis by 80% within 24 hours.

• Agricultural and Veterinary Protection

Antibody-coated feed additives bind mycotoxins in livestock diets, preventing absorption and improving animal growth rates. Trials show zearalenone-neutralizing agents reduce sow infertility by 40% in contaminated feed environments.

• Biomarker Discovery and Mechanistic Research

Antibodies enable precise tracking of mycotoxin metabolites in tissues, advancing pharmacokinetic models and identifying novel detoxification targets.

Our Anti-Mycotoxin Neutralizing Antibodies

Creative Biolabs' antibodies are engineered to neutralize mycotoxins through high-specificity binding, blocking toxin-receptor interactions and mitigating cytotoxicity. Key features include:

- Broad-Spectrum Recognition: Cross-reactive clones targeting aflatoxin M1, ochratoxin A, and T-2 toxin.

- High Sensitivity: Detection limits ≤0.1 ppb in complex matrices (e.g., grains, serum).

- Thermal Stability: Retain activity after prolonged storage at 4°C, ideal for field applications.

Creative Biolabs offers mycotoxin specific Neutra™ antibody products that are engineered to overcome detection and therapeutic challenges in mycotoxin research. With unmatched specificity, sensitivity, and scalability, our solutions empower industries to safeguard health and enhance productivity.

Contact our team today to explore tailored antibody solutions for your project.

REFERENCE

• Li, Tian, et al. "Mycotoxin-Caused Intestinal Toxicity: Underlying Molecular Mechanisms and Further Directions." Toxics 13.8 (2025): 625. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/toxics13080625